Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.

Menopause (New York, N.Y.) - 1 Jan 2020

Perri Tamar, Farhadian Yasmin, Friedman Eitan, Korach Jacob

Abstract excerpt

OBJECTIVE: BRCA-mutation carriers are offered risk-reducing bilateral salpingo-oophorectomy (RRBSO) at age 35 to 40 years, leading to major life-quality and health-related issues associated with early menopause. Hormone therapy (HT) may significantly alleviate menopausal symptoms without increasing breast or ovarian cancer risk in BRCA carriers. We investigated attitudes of Israeli healthcare providers to HT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA1
Share to Genes, BRCA2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Health Knowledge, Attitudes, Practice

Share to Health Personnel

Share to Hormone Replacement Therapy

Share to Israel

Share to Menopause, Premature

Share to Salpingo-oophorectomy

Source

Identifiers

PMID: 31688415
DOI: 10.1097/GME.0000000000001432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.PMID 31688415Read ↗

BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.Semantic proximity Read ↗

A pilot study of BRCA mutation carriers' knowledge about the clinical impact of prophylactic-oophorectomy and views on fertility consultation: a single-center pilot study.Semantic proximity Read ↗

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.Semantic proximity Read ↗

Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers.Semantic proximity Read ↗

Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriersSemantic proximity Read ↗

Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer.Semantic proximity Read ↗

Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.Semantic proximity Read ↗

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Semantic proximity Read ↗

Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.Semantic proximity Read ↗

[Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries].Semantic proximity Read ↗

Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy among diverse patients with BRCA mutations at an urban public hospital: a mixed methods study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.